Psychological Support and Psycho-Emotional Trajectories in Cancer Genetics. (PsyOncoGen)
Apport d'un Accompagnement Psychologique au Cours du Parcours en oncogénétique : étude de la Trajectoire Psycho-émotionnelle Des Consultants
研究概览
地位
干预/治疗
- 其他：Patients undergoing their first cancer genetic testing consultation who choose to utilise the clinical psychological support offered by the unit
- 其他：Patients undergoing their first cancer genetic testing consultation who choose to follow the care pathway without utilising the systematically offered clinical psychological support.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名：Jérôme Lambert, MD PhD
- 电话号码：+33 0142499742
- 邮箱：jerome.lambert@u-paris.fr
研究联系人备份
- 姓名：Marie-Charlotte Villy, MD
- 电话号码：+33 01.42.49.47.98
- 邮箱：marie-charlotte.villy@aphp.fr
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adult individuals referred for their first genetic counselling consultation, with an indication for a genetic test;
- Individuals capable of understanding and expressing themselves sufficiently in French (able to complete questionnaires and participate in interviews);
- Must not present with neurocognitive or psychopathological disorders, or impairments that could compromise their understanding of the study and informed decision-making regarding participation;
- Affected or unaffected index case or relatives.
Exclusion Criteria:
- Individuals under guardianship, curatorship, or a legal protection order, or deprived of liberty by a judicial or administrative decision;
- Individuals presenting with neurocognitive or psychopathological disorders and/or linguistic difficulties that preclude understanding the study and questionnaires, or participating in an informed manner;
- Individuals already enrolled in a hereditary cancer testing care pathway.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Psychological Support Group
|
This includes structured clinical interviews with the unit's psychologist within 15 days following the initial consultation (T1), 15 days following result disclosure (T2), and 2.5 months post-disclosure.
Patients can change their choice at any point if their support needs change.
|
|
Group Without Psychological Support
|
To ensure equity of care, these patients maintain the right to request and access the psychological support program at any time during their pathway if their needs change.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Longitudinal study of Psycho-Emotional Distress Scores
大体时间：Up to 9 months
|
Evaluated using the scores of the Hospital Anxiety and Depression Scale (HADS) at each key milestone to compare longitudinal trajectories between patients receiving psychological support and those who do not. The HADS is a 14-item self-report questionnaire consisting of an Anxiety subscale (7 items, score range 0-21) and a Depression subscale (7 items, score range 0-21), yielding a total distress score range from 0 to 42. Higher scores indicate greater severity of psycho-emotional distress. Assessed at three key time points: initial consultation (T1), the genetic test result disclosure (T2), and at three months post-disclosure (T3). |
Up to 9 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Evolution of Psycho-Emotional Distress Post-Disclosure.
大体时间：Up to 9 months
|
Measured using the Hospital Anxiety and Depression Scale (HADS) scores to analyse the evolution of general distress. Data will be analysed based on the type of genetic result (pathogenic variant, variant of uncertain significance, negative result), the specific primary cancer site and patient demographics (age, sex, etc.). Measured from genetic test result disclosure (T2) to the three-month post-disclosure follow-up (T3). |
Up to 9 months
|
|
Specific Hereditary Cancer Psychosocial Concerns.
大体时间：Up to 9 months
|
Measured using the French version of the Psychosocial Aspects of Hereditary Cancer questionnaire, to study specific psychosocial needs. For each of the 6 distinct dimensions, raw scores are summed and normalised to a 0-100 scale. A higher score represents increasing psychosocial difficulties and challenges within the specific dimension. Assessed at initial genetics consultation (T1), genetic test result disclosure (T2), and three-month post-disclosure (T3). |
Up to 9 months
|
|
Interrelations and variations of Emotional Distress and Psychosocial Concerns (HADS & PAHC-French).
大体时间：Up to 9 months
|
Evaluated using the concurrent scores of both of the HADS and PAHC-French questionnaires to explore the relations between general emotional distress and specific psychosocial concerns in clinical cancer genetics. Assessed at initial genetics consultation (T1), genetic test result disclosure (T2), and three months post-disclosure (T3). |
Up to 9 months
|
|
Clinical Psychological Trajectories and Psychological Support Adherence
大体时间：Up to 9 months
|
Based on the qualitative clinical assessment and follow-up notes compiled by the unit's clinical psychologist. This metric is used to describe the participant's real-world psychological pathways, specifically tracking and documenting any adjustments or changes in their use of psychological support throughout the care pathway. Documented within 15 days following T1, T2 and 2.5 months after T2, following each interview with the clinical psychologist. |
Up to 9 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.